<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Heparin versus placebo for non‐ST elevation acute coronary syndromes - Andrade-Castellanos, CA - 2014 | Cochrane Library</title> <meta content="Heparin versus placebo for non‐ST elevation acute coronary syndromes - Andrade-Castellanos, CA - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003462.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Heparin versus placebo for non‐ST elevation acute coronary syndromes - Andrade-Castellanos, CA - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003462.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003462.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Heparin versus placebo for non‐ST elevation acute coronary syndromes" name="citation_title"/> <meta content="Carlos A Andrade-Castellanos" name="citation_author"/> <meta content='Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"' name="citation_author_institution"/> <meta content="caandrade@hcg.gob.mx" name="citation_author_email"/> <meta content="Luis Enrique Colunga-Lozano" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Netzahualpilli Delgado-Figueroa" name="citation_author"/> <meta content="Hospital Civil de Guadalajara Dr. Juan I. Menchaca" name="citation_author_institution"/> <meta content="Kirk Magee" name="citation_author"/> <meta content="Dalhousie University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD003462.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/06/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003462.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003462.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003462.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Coronary Syndrome [*drug therapy, mortality]; Angina, Unstable [drug therapy]; Anticoagulants [adverse effects, *therapeutic use]; Heparin [adverse effects, *therapeutic use]; Heparin, Low-Molecular-Weight [adverse effects, therapeutic use]; Myocardial Infarction [prevention &amp; control]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003462.pub3&amp;doi=10.1002/14651858.CD003462.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003462\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003462\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003462.pub3",title:"Heparin versus placebo for non\\u2010ST elevation acute coronary syndromes",firstPublishedDate:"Jun 27, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003462.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003462.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003462.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003462.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003462.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003462.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003462.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003462.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003462.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003462.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3808 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003462.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-sec-0050"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-sec-0012"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-sec-0013"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-sec-0033"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-sec-0048"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/appendices#CD003462-sec-0055"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/supinfo/CD003462StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/supinfo/CD003462StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Heparin versus placebo for non‐ST elevation acute coronary syndromes</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information#CD003462-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Carlos A Andrade-Castellanos</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information#CD003462-cr-0005">Luis Enrique Colunga-Lozano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information#CD003462-cr-0006">Netzahualpilli Delgado-Figueroa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information#CD003462-cr-0007">Kirk Magee</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information/en#CD003462-sec-0067">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 June 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003462.pub3">https://doi.org/10.1002/14651858.CD003462.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003462-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003462-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003462-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003462-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003462-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003462-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003462-abs-0001" lang="en"> <section id="CD003462-sec-0001"> <h3 class="title" id="CD003462-sec-0001">Background</h3> <p>Non‐ST elevation acute coronary syndromes (NSTEACS) represent a spectrum of disease including unstable angina and non‐ST segment myocardial infarction (NSTEMI). Despite treatment with aspirin, beta‐blockers and nitroglycerin, unstable angina/NSTEMI is still associated with significant morbidity and mortality. Although evidence suggests that low molecular weight heparin (LMWH) is more efficacious compared to unfractionated heparin (UFH), there is limited data to support the role of heparins as a drug class in the treatment of NSTEACS. This is an update of a review last published in 2008. </p> </section> <section id="CD003462-sec-0002"> <h3 class="title" id="CD003462-sec-0002">Objectives</h3> <p>To determine the effect of heparins (UFH and LMWH) compared with placebo for the treatment of patients with non‐ST elevation acute coronary syndromes (unstable angina or NSTEMI). </p> </section> <section id="CD003462-sec-0003"> <h3 class="title" id="CD003462-sec-0003">Search methods</h3> <p>For this update the Cochrane Heart Group Trials Search Co‐ordinator searched the Cochrane Central Register of Controlled Trials on <i>The Cochrane Library</i> (2013, Issue 12), MEDLINE (OVID, 1946 to January week 1 2014), EMBASE (OVID, 1947 to 2014 week 02), CINAHL (1937 to 15 January 2014) and LILACS (1982 to 15 January 2014). We applied no language restrictions. </p> </section> <section id="CD003462-sec-0004"> <h3 class="title" id="CD003462-sec-0004">Selection criteria</h3> <p>Randomized controlled trials of parenteral UFH or LMWH versus placebo in people with non‐ST elevation acute coronary syndromes (unstable angina or NSTEMI). </p> </section> <section id="CD003462-sec-0005"> <h3 class="title" id="CD003462-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed quality of studies and independently extracted data. </p> </section> <section id="CD003462-sec-0006"> <h3 class="title" id="CD003462-sec-0006">Main results</h3> <p>There were no new included studies for this update. Eight studies (3118 participants) were included in this review. We found no evidence for difference in overall mortality between the groups treated with heparin and placebo (risk ratio (RR) = 0.84, 95% confidence interval (CI) 0.36 to 1.98). Heparins compared with placebo, reduced the occurrence of myocardial infarction in patients with unstable angina and NSTEMI (RR = 0.40, 95% CI 0.25 to 0.63, number needed to benefit (NNTB) = 33). There was a trend towards more major bleeds in the heparin studies compared to control studies (RR = 2.05, 95% CI 0.91 to 4.60). From a limited data set, there appeared to be no difference between patients treated with heparins compared to control in the occurrence of thrombocytopenia (RR = 0.20, 95% CI 0.01 to 4.24). Assessment of overall risk of bias in these studies was limited as most of the studies did not give sufficient detail to allow assessment of potential risk of bias. </p> </section> <section id="CD003462-sec-0007"> <h3 class="title" id="CD003462-sec-0007">Authors' conclusions</h3> <p>Compared with placebo, patients treated with heparins had a similar risk of mortality, revascularization, recurrent angina, and thrombocytopenia. However, those treated with heparins had a decreased risk of myocardial infarction and a higher incidence of minor bleeding. Overall, the evidence assessed in this review was classified as low quality according to the GRADE approach. The results presented in this review must therefore be interpreted with caution. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003462-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003462-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003462-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003462-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003462-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003462-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003462-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003462-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003462-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003462-abs-0002" lang="en"> <h3>Heparins reduce the number of heart attacks but caused more minor bleeding after non‐ST elevation acute coronary syndromes compared with placebo </h3> <p>Blood clots in the arteries leading to the heart can cause acute coronary syndromes: unstable angina (a feeling of tightness in the chest) or a type of heart attack (non‐ST segment myocardial infarction ‐ NSTEMI). Drugs that prevent clots from forming (such as aspirin) or thin the blood (such as heparin) can relieve the problem. Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are two types of heparin. This review of trials found that UFH and LMWH when given to patients with high‐risk unstable angina or NSTEMI in the acute phase of treatment, in addition to standard therapy with aspirin, prevent more heart attacks than placebo but do not reduce mortality, the need for revascularization procedures or recurrent angina. Although there was limited reporting of side‐effects, heparins caused more cases of minor bleeding. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003462-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003462-sec-0050"></div> <h3 class="title" id="CD003462-sec-0051">Implications for practice</h3> <section id="CD003462-sec-0051"> <p>This systematic review of randomized controlled trials supports the use of heparins in the early treatment of non‐ST elevation acute coronary syndromes. Given in addition to aspirin to patients with a history of typical angina accompanied by either a past medical history of coronary artery disease or ECG/cardiac enzyme changes, heparins reduced the incidence of myocardial infarction, but not mortality. In this review, heparins were given within 24 to 72 hours of the onset of symptoms as a weight‐adjusted dose for a five to eight day period, with most studies administering it for two to seven days. The small number of studies makes it impossible to recommend a particular dosing regimen. Indirect comparisons of the pooled results of trials of UFH versus placebo with the pooled results of trials of LMWH versus placebo may be interpreted as suggesting that LMWH is more effective than UFH as a subgroup. However, indirect comparisons are unreliable and potentially misleading because of differences in the kinds of patients randomized, outcome definitions, and treatment regimens. </p> </section> <h3 class="title" id="CD003462-sec-0052">Implications for research</h3> <section id="CD003462-sec-0052"> <p>Despite the strength of the findings of this review, there are several areas in which questions remain unanswered. </p> <p> <ul id="CD003462-list-0008"> <li> <p>Currently, the optimal time of treatment initiation is unclear. The eight studies examined three different time periods: within 24, 48 and 72 hours. It would be interesting to determine whether the timing of heparin administration (in the emergency department versus on the ward) affects outcomes. </p> </li> <li> <p>Given the interventional nature of the investigation and treatment of acute coronary syndromes, the optimal duration of heparin treatment remains controversial. Whether shorter duration treatments might be as effective remains an interesting, yet unresolved, question. </p> </li> <li> <p>Patient‐centered outcomes such as quality of life have not been studied and are particularly warranted. In addition, considering the cost of these drugs, prospective cost‐effectiveness analyses will be desirable. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003462-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003462-sec-0008"></div> <div class="table" id="CD003462-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin versus placebo for non‐ST elevation acute coronary syndromes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Heparin versus placebo for non‐ST elevation acute coronary syndromes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with non‐ST elevation acute coronary syndromes<br/><b>Settings:</b> Inpatients<br/><b>Intervention:</b> Heparin<br/><b>Comparison:</b> Placebo or untreated control </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Heparin + ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 5‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.84</b> <br/>(0.36 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2426<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low due to study limitations and imprecision</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(3 to 18) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of myocardial infarction</b><br/>Follow‐up: 5‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.4</b> <br/>(0.25 to 0.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2426<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low quality because of very serious study limitations</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(12 to 30) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(15 to 37) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Recurrent angina</b><br/>Follow‐up: 5‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.81</b> <br/>(0.6 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2426<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Very low due to study limitations and inconsistency</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>166 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>134 per 1000</b><br/>(99 to 181) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>361 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b><br/>(217 to 393) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of revascularization procedures</b><br/>Follow‐up: 5‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b> <br/>(0.76 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2520<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low quality because of very serious study limitations</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b><br/>(73 to 111) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b><br/>(103 to 155) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Major hemorrhage</b><br/>Follow‐up: 2‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.05</b> <br/>(0.91 to 4.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3118<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low quality because of very serious study limitations</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b><br/>(4 to 21) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Allocation concealment was uncertain in the majority of the evaluated trials. Lack of blinding of participants and outcome assessors in two trials, blinding of outcome assessors is uncertain in three trials. Final decision: rate down by one level (lack of blinding not considered a serious study limitation for the outcome of all‐cause mortality). Two trials stopped early for benefit; stopping early as a source of bias is questionable. Final decision was not to rate down for stopping early for benefit.<br/><sup>2</sup> Wide confidence intervals and few events. We decided to rate down for imprecision because confidence intervals fails to exclude important benefit or important harm.<br/><sup>3</sup> Funnel plot could be interpreted as suggesting of publication bias. However, the number of studies is insufficient to meet rigorous criteria for creating a funnel plot. Final decision: publication bias is speculative (not rate down).<br/><sup>4</sup> Allocation concealment was uncertain in the majority of the evaluated trials. Lack of blinding of participants in four trials, lack of blinding of outcome assessors in two trials, blinding of outcome assessors is uncertain in three trials. Final decision: rate down by two levels.Two trials stopped early for benefit; stopping early as a source of bias is questionable. Final decision was not to rate down for stopping early for benefit.<br/><sup>5</sup> Allocation concealment was uncertain in the majority of the evaluated trials. Lack of blinding of participants in four trials, lack of blinding of outcome assessors in two trials, blinding of outcome assessors is uncertain in five trials. Final decision: rate down by two levels.Two trials stopped early for benefit; stopping early as a source of bias is questionable. Final decision was not to rate down for stopping early for benefit. </p> <p><sup>6</sup> Results were inconsistent across studies as evidenced by I² = 65% </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003462-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003462-sec-0009"></div> <p>Acute coronary syndromes represent a spectrum of disease ranging from unstable angina to non‐ST segment myocardial infarction (NSTEMI) and ST‐segment elevation myocardial infarction (STEMI). The pathophysiology of non‐ST segment elevation acute coronary syndromes (NSTEACS), i.e. unstable angina and NSTEMI, involves the rupture or erosion of an atherosclerotic coronary plaque (<a href="./references#CD003462-bbs2-0073" title="FalkE , ShahP , FusterV . Coronary plaque disruption. Circulation1995;92(3):657-71.">Falk 1995</a>), activation of the coagulation cascade, and adhesion, activation and platelet aggregation. Inflammation plays a central role in the pathogenesis of atherosclerosis. Macrophage infiltration of plaque is key to this process (<a href="./references#CD003462-bbs2-0078" title="LibbyP , RidkerPM , MaseriA . Inflammation and atherosclerosis. Circulation2002;105:1135-43.">Libby 2002</a>). Until recently, a significant proportion of patients admitted with unstable angina progressed to myocardial infarction or died in hospital (<a href="./references#CD003462-bbs2-0067" title="CairnsJA , J Singer, M Gent, HolderDA , RogersD , SackettDL , et al. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or chest pain in Hamilton, Ontario, a city of 375,000 people. Canadian Journal of Cardiology1989;319:239-46.">Cairns 1989</a>; <a href="./references#CD003462-bbs2-0068" title="CohenM . Approaches to the treatment of unstable angina and non-Q wave myocardial infarction. Canadian Journal of Cardiology1998;14(Suppl E):11E-14E.">Cohen 1998</a>). </p> <p>NSTEMI may be differentiated from unstable angina by the presence of elevated cardiac enzymes indicating actual progression to myocardial necrosis and infarction. Initially, however, the two entities may present identically. Both unstable angina and NSTEMI are differentiated from STEMI in that they are not amenable to either immediate reperfusion therapy with systemic fibrinolytic therapy or immediate percutaneous coronary intervention (PCI). The TIMI III trial assessed the role of fibrinolysis in NSTEACS. This trial evaluated patients with unstable angina or NSTEMI and objective evidence of coronary artery disease. Patients were treated with intravenous heparin and then randomly assigned to placebo or infusion of alteplase. Alteplase administration was not associated with any improvement in primary end points (death or myocardial infarction) at six weeks or one year (<a href="./references#CD003462-bbs2-0065" title="AndersonHV , CannonCP , StonePH , WilliamsDO , McCabeCH , KnatterudGL , et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. Journal of the American College of Cardiology1995;26(7):1643-50.">Anderson 1995</a>; <a href="./references#CD003462-bbs2-0082" title="The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation1994;89(4):1545-56.">TIMI IIIB 1994</a>). There was also a trend toward a higher incidence of severe hemorrhagic events in the alteplase group, with intracerebral hemorrhage occurring in four patients versus no controls. Early risk assessment using a risk stratification tool, such as the TIMI risk score is recommended to guide the timing of coronary angiography and possible PCI in patients with NSTEACS (<a href="./references#CD003462-bbs2-0071" title="HammCW , BassandJP , AgewallS , BaxJ , BoersmaE , BuenoH , et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal2011;32(23):2999-3054.">ESC Guidelines NSTEACS 2011</a>). </p> <p>Given the role of thrombin in the pathogenesis of acute coronary syndromes, heparin has the potential to decrease the occurrence of these undesirable outcomes. Unfractionated heparin (UFH) is a heterogenous mixture of polysaccharide chains whose mechanism of action is mediated through a unique pentasaccharide with a high affinity for antithrombin III. This bond produces a conformational change that increases the ability of antithrombin III to deactivate thrombin, factor Xa and factor IXa. Unfortunately, only one third of the UFH molecules have antithrombin III activity and UFH non‐specific binding to protein and cells results in a less predictable dose‐response curve (<a href="./references#CD003462-bbs2-0076" title="HirshJ , WarkentinTE , RaschkeR , GrangerC , OhmanEM , DalenJE . Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest1998;114:489S-510S.">Hirsh 1998</a>). Low molecular weight heparin (LMWH), which is derived from the depolymerization of standard UFH into lower molecular weight fragments, has a number of theoretical advantages including a more predictable dose‐response curve, longer half‐life and a lower incidence of heparin‐induced thrombocytopenia which may be explained by reduced binding to platelets (<a href="./references#CD003462-bbs2-0084" title="WeitzJE . Low molecular weight heparins. New England Journal of Medicine1997;337:688-98.">Weitz 1997</a>). Evidence suggests that LMWH is more efficacious compared to UFH (<a href="./references#CD003462-bbs2-0070" title="EikelboomJW , AnandSS , MalmbergK , WeitzJI , GinsbergJS , YusufS . Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet2000;355(9219):1936-42.">Eikelboom 2000</a>; <a href="./references#CD003462-bbs2-0079" title="MageeKD , SevcikW , MoherD , RoweBH . Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes (Cochrane Review). Cochrane Database of Systematic Reviews2003, Issue 1. Art. No: CD002132. [DOI: 10.1002/14651858.CD002132]">Magee 2003</a>), but current guidelines recommend anticoagulation with any form of heparin (LWWH or UFH) for all patients presenting with unstable angina or NSTEMI in addition to antiplatelet therapy (<a href="./references#CD003462-bbs2-0064" title="AndersonJL , AdamsCD , AntmanEM , BridgesCR , CaliffRM, Casey DE Jr, et al. 2012 ACCF/AHA focused update incorporated into the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines. Journal of the American College of Cardiology2013;61(23):e179–347.">ACCF/AHA Guideline NSTEACS 2013</a>; <a href="./references#CD003462-bbs2-0071" title="HammCW , BassandJP , AgewallS , BaxJ , BoersmaE , BuenoH , et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal2011;32(23):2999-3054.">ESC Guidelines NSTEACS 2011</a>). </p> <section id="CD003462-sec-0010"> <h3 class="title" id="CD003462-sec-0010">Adverse effects of the intervention</h3> <p>Hemorrhage is the chief complication that may result from heparin therapy. By inhibiting blood coagulation, the heparins, generally cause a balancing act between prevention of thrombus formation and inhibition of physiological coagulation. The incidence of bleeding under heparin therapy is hard to define, as it depends on numerous parameters including the indication, dosage, method, and duration of heparin application, the definition of bleeding, patient characteristics and determinants of bleeding such as surgery and co‐medication. In clinical trials, up to 30% of patients with acute coronary syndromes or undergoing PCI experience bleeding complications (<a href="./references#CD003462-bbs2-0080" title="ManoukianSV , VoeltzMD , EikelboomJ . Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. Clinical Cardiology2007;10(2):II24-34.">Manoukian 2007</a>). Heparin‐induced thrombocytopenia is a life‐threatening disorder that follows exposure to UFH or (less commonly) LMWH. Patients classically present with a low platelet count (&lt;150,000 per cubic millimeter) or a relative decrease of 50% or more from baseline (<a href="./references#CD003462-bbs2-0083" title="WarkentinTE , RobertsRS , HirshJ , KeltonJG . An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Archives of Internal Medicine2003;163(20):2518-24.">Warkentin 2003</a>). The incidence of heparin‐induced thrombocytopenia is variable and is influenced by the heparin formulation and the clinical context in which heparin is administered. </p> </section> <section id="CD003462-sec-0011"> <h3 class="title" id="CD003462-sec-0011">Why it is important to do this review</h3> <p>Systematic reviews have shown a reduction in the risk of death or myocardial infarction in patients with unstable angina and NSTEMI treated with aspirin plus heparin compared with those treated with aspirin alone (<a href="./references#CD003462-bbs2-0070" title="EikelboomJW , AnandSS , MalmbergK , WeitzJI , GinsbergJS , YusufS . Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet2000;355(9219):1936-42.">Eikelboom 2000</a>; <a href="./references#CD003462-bbs2-0045" title="OlerA , WhooleyMA , OlerJ , GradyD . Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA1996;276:811-5. ">Oler 1996</a>). Eikelboom et al. assessed the short‐term and long‐term effects of UFH and LMWH in patients with acute coronary syndromes without ST elevations. The comparisons included UFH and LMWH with placebo or untreated control, and UFH versus LMWH. Overall, short‐term UFH or LMWH reduced the incidence of non‐fatal myocardial infarction and death by 50%. However, there are some important limitations in these reviews. Firstly, the comprehensiveness of systematic literature searches is far from optimal. For instance, the literature search by Oler et al. was restricted exclusively to MEDLINE (<a href="./references#CD003462-bbs2-0045" title="OlerA , WhooleyMA , OlerJ , GradyD . Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA1996;276:811-5. ">Oler 1996</a>); therefore, it is possible that relevant studies may have been overlooked. Secondly, assessments of risk of bias of studies are not specified in both reviews (<a href="./references#CD003462-bbs2-0070" title="EikelboomJW , AnandSS , MalmbergK , WeitzJI , GinsbergJS , YusufS . Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet2000;355(9219):1936-42.">Eikelboom 2000</a>; <a href="./references#CD003462-bbs2-0045" title="OlerA , WhooleyMA , OlerJ , GradyD . Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA1996;276:811-5. ">Oler 1996</a>). Assessing the risk of bias of a study can be thought of as assessing the risk that the study results reflect bias in study design or execution rather than the true effect of the intervention or exposure under study. Risk of bias is interchangeable with internal validity and may overlap to a great extent with quality. Given the limitations of previous systematic reviews, we used specific methodology and criteria outlined by The Cochrane Collaboration to present a comprehensive systematic review of heparins (UFH and LMWH) in the acute treatment of NSTEACS. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003462-sec-0012" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003462-sec-0012"></div> <p>To update the previously published review that examined the effects of heparin compared with placebo for the treatment of patients with non‐ST elevation acute coronary syndromes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003462-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003462-sec-0013"></div> <section id="CD003462-sec-0014"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003462-sec-0015"> <h4 class="title">Types of studies</h4> <p>To be considered, clinical studies were required to be randomized controlled trials, including multi‐arm trials. Blinding was not a requirement. </p> </section> <section id="CD003462-sec-0016"> <h4 class="title">Types of participants</h4> <p>Only studies that included adult patients (&gt; 18 years of age) presenting with non‐ST elevation acute coronary syndromes requiring treatment within 72 hours of presentation of their last episode of chest pain were considered eligible for inclusion. Non‐ST elevation acute coronary syndromes included unstable angina and NSTEMI. Unstable angina had to be characterized as typical chest pain lasting at least 10 minutes within 72 hours of presentation with either historic, electrocardiographic or angiographic evidence of underlying ischemic heart disease. NSTEMI had to be characterized as chest pain with ST segment depression and elevation of relative cardiac enzymes (total creatine kinase (CK) greater than twice the usual upper limit or CK‐MB greater than the upper normal limit). Those studies where the patients were inpatients, had stable angina, were volunteers, or presented to non‐Emergency Department settings were excluded. </p> </section> <section id="CD003462-sec-0017"> <h4 class="title">Types of interventions</h4> <p>All patients were required to receive aspirin therapy and be randomized to receive treatment with either parenteral unfractionated heparin (UFH) or low molecular weight heparin (LMWH) compared with placebo or untreated control within 72 hours of presentation. Because platelets play an important role in the development of thrombosis, antiplatelet agents are a mainstay of the treatment of non‐ST elevation acute coronary syndromes. Aspirin is recommended by guidelines as acute and long‐term treatment for all patients with non‐ST elevation acute coronary syndromes unless it is contraindicated (<a href="./references#CD003462-bbs2-0064" title="AndersonJL , AdamsCD , AntmanEM , BridgesCR , CaliffRM, Casey DE Jr, et al. 2012 ACCF/AHA focused update incorporated into the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines. Journal of the American College of Cardiology2013;61(23):e179–347.">ACCF/AHA Guideline NSTEACS 2013</a>; <a href="./references#CD003462-bbs2-0071" title="HammCW , BassandJP , AgewallS , BaxJ , BoersmaE , BuenoH , et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal2011;32(23):2999-3054.">ESC Guidelines NSTEACS 2011</a>). By the time of the original review, aspirin was the standard of care for patients with unstable angina and NSTEMI. </p> <section id="CD003462-sec-0018"> <h5 class="title">Intervention</h5> <p> <ul id="CD003462-list-0001"> <li> <p>Parenteral UFH or LMWH.</p> </li> </ul> </p> </section> <section id="CD003462-sec-0019"> <h5 class="title">Comparator</h5> <p> <ul id="CD003462-list-0002"> <li> <p>Placebo or untreated control.</p> </li> </ul> </p> </section> </section> <section id="CD003462-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Only studies reporting clinically relevant outcomes were considered. Outcomes over all time periods were considered. Outcomes included the following. </p> <section id="CD003462-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003462-list-0003"> <li> <p>Death (all‐cause mortality).</p> </li> <li> <p>Myocardial infarction.</p> </li> <li> <p>Major hemorrhage (e.g. fall in hemoglobin level of &gt;2 g/dL, requires transfusion, is intracranial, retroperitoneal, or intraocular, or causes death or cessation of the study treatment). </p> </li> </ul> </p> </section> <section id="CD003462-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003462-list-0004"> <li> <p>Recurrent angina (e.g. anginal chest pain that requires nitroglycerin infusion to be restarted). </p> </li> <li> <p>Revascularization procedures (e.g. angioplasty with or without stenting, coronary artery bypass grafting). </p> </li> <li> <p>Minor hemorrhage (e.g. any clinically important bleed that does not qualify as major; e.g. epistaxis, ecchymosis or hematoma, or macroscopic hematuria). </p> </li> <li> <p>Adverse events other than hemorrhage (thrombocytopenia).</p> </li> </ul> </p> </section> </section> </section> <section id="CD003462-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We updated the previously‐run searches from 2002 and searched the following databases up to 15 January 2014: </p> <p> <ul id="CD003462-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) on <i>The Cochrane Library</i> (2013, Issue 12); </p> </li> <li> <p>MEDLINE (OVID, 1946 to January week 1 2014);</p> </li> <li> <p>EMBASE Classic + EMBASE (OVID, 1974 to 2014 week 2);</p> </li> <li> <p>CINAHL (EBSCO, 1937 to 15 January 2014);</p> </li> <li> <p>LILACS (Bireme, 1982 to 15 January 2014).</p> </li> </ul> </p> <p>The search strategies are listed in the <a href="./appendices#CD003462-sec-0056">Appendix 1</a>. For this update, the randomized controlled trial (RCT) filter for MEDLINE is the Cochrane sensitivity and precision maximizing RCT filter, and for EMBASE, terms as recommended in <i>the</i> <i>Cochrane Handbook for Systematic Reviews of Interventions</i> have been applied. (<a href="./references#CD003462-bbs2-0075" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Chichester (UK): John Wiley &amp; Sons, 2011.">Higgins 2011</a>). The RCT filter for CINAHL is based on SIGN and Cochrane filter terms (<a href="./references#CD003462-bbs2-0075" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Chichester (UK): John Wiley &amp; Sons, 2011.">Higgins 2011</a>). </p> </section> <section id="CD003462-sec-0024"> <h3 class="title" id="CD003462-sec-0024">Data collection and analysis</h3> <section id="CD003462-sec-0025"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KM and BR) scanned the titles and abstracts of each record retrieved from the searches for the original review. A new review author (CAC) did this for the update. If information in the title and abstract clearly indicated that the trial did not meet the inclusion criteria, we rejected the trial. When a title or abstract could not be rejected with certainty, we obtained the full‐text article, and two review authors (KM and BR for original review; CAC and LCL for the update) independently inspected it. We resolved any uncertainties or disagreements on whether papers were eligible for inclusion by consensus in the presence of a third investigator. If we excluded a trial, we recorded both the article citation and the reason for exclusion. </p> </section> <section id="CD003462-sec-0026"> <h4 class="title">Data extraction and management</h4> <p>For the original review, two review authors (BR, KM) independently extracted data using a standardized form (data extraction sheet based on the Cochrane Consumers and Communication Review Group’s data extraction template). Discrepancies were resolved through consensus or in consultation with a third author. </p> <p>Data extraction included the following items.</p> <p> <ul id="CD003462-list-0006"> <li> <p>Population: age, gender, time to presentation, inclusion and exclusion criteria</p> </li> <li> <p>Type of intervention and control: agent, dose, duration of therapy, weight‐based versus fixed dosing, target activated partial thromboplastin time (aPTT), time to adequate aPTT, and control used </p> </li> <li> <p>Outcome: timing of primary outcome, assessors, adjudication, definition of: myocardial infarction, unstable angina, mortality </p> </li> <li> <p>Side‐effect profile: designation of minor and major bleeding</p> </li> <li> <p>Design: parallel group versus cross‐over; method of randomization, blinding and follow‐up</p> </li> </ul> </p> </section> <section id="CD003462-sec-0027"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CAC and NDF for the update) independently assessed risk of bias in the included studies using The Cochrane Collaboration ‘Risk of bias’ tool (<a href="./references#CD003462-bbs2-0075" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Chichester (UK): John Wiley &amp; Sons, 2011.">Higgins 2011</a>), as described in Chapter 8 of <i>the</i> <i>Cochrane Handbook for Systematic Reviews of Interventions.</i> Any disagreements concerning risk of bias were resolved by discussion. We displayed the results by creating a ’Risk of bias’ summary (<a href="#CD003462-fig-0001">Figure 1</a>) and a ’Risk of bias’ graph (<a href="#CD003462-fig-0002">Figure 2</a>) using RevMan 5.2 software. For each domain of risk of bias, we described what was reported to have happened in the study in order to provide a rationale for the second part, which involved assigning a judgement of 'Low risk’ of bias, 'High risk’ of bias, or 'Unclear risk’ of bias. For each included study, we assessed the following seven domains of risk of bias. </p> <div class="figure" id="CD003462-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003462-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD003462-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003462-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p> <ul id="CD003462-list-0007"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selecting reporting (reporting bias)</p> </li> <li> <p>Other bias</p> </li> </ul> </p> </section> <section id="CD003462-sec-0028"> <h4 class="title"><i>Measures of treatment effect</i> </h4> <p>All trials were combined using Review Manager, version 5.2 (Nordic Cochrane Centre, Copenhagen, Denmark). For dichotomous variables, individual and pooled statistics were calculated as risk ratios (RR) with 95% confidence intervals (95% CI). DerSimonian–Laird random‐effects models (<a href="./references#CD003462-bbs2-0069" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1987;7(3):177-88.">DerSimonian 1987</a>) were used when more than five trials were pooled. When fewer trials or no heterogeneity was identified, a fixed‐effect model was employed. If identified, for continuous outcomes, we planned to calculate individual and pooled statistics as mean differences (MD) or standardized mean differences (SMD) and 95% CIs using a random‐effects model. The presence of publication bias was examined visually using a funnel plot. </p> </section> <section id="CD003462-sec-0029"> <h4 class="title">Assesment of heterogeneity</h4> <p>The impact of statistical heterogeneity was quantified using the I<sup>2</sup> statistic. The thresholds of I<sup>2</sup> recommended by <i>the Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003462-bbs2-0075" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Chichester (UK): John Wiley &amp; Sons, 2011.">Higgins 2011</a>) are:<br/>• 0% to 40%: might not be important;<br/>• 30% to 60%: may represent moderate heterogeneity;<br/>• 50% to 90%: may represent substantial heterogeneity;<br/>• 75% to 100%: considerable heterogeneity. </p> <p>We used subgroup analyses planned a priori to investigate possible differences between the studies. </p> </section> <section id="CD003462-sec-0030"> <h4 class="title">Subgroup analysis</h4> <p>Two specific subgroups were planned a priori:</p> <p>a) Population: unstable angina versus unstable angina and NSTEMI; and<br/>b) Intervention: UFH versus LMWH. </p> </section> <section id="CD003462-sec-0031"> <h4 class="title">Sensitivity analysis</h4> <p>Possible sources of heterogeneity were assessed by sensitivity analysis that included only trials of good quality. We defined a good‐quality study as one which fulfils all of the following criteria: adequate allocation concealment, blinding of outcome assessment and data analysis performed according to the intention‐to‐treat principle. </p> </section> <section id="CD003462-sec-0032"> <h4 class="title">Summary of findings</h4> <p>For this update, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for evaluating quality of the evidence of systematic reviews (<a href="./references#CD003462-bbs2-0075" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Chichester (UK): John Wiley &amp; Sons, 2011.">Higgins 2011</a>) was adopted using the software GRADEprofiler. The quality of the body of evidence was assessed with reference to the overall risk of bias of the included studies, the directness of the evidence, the inconsistency of the results, the precision of the estimates, and the risk of publication bias. The quality of the body of evidence was classified into four categories: high, moderate, low and very low. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003462-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003462-sec-0033"></div> <section id="CD003462-sec-0034"> <h3 class="title">Description of studies</h3> <section id="CD003462-sec-0035"> <h4 class="title">Results of the search</h4> <p>The computerized search of EMBASE, MEDLINE and CINAHL of the original review (2002) identified 2193 original publication citations. Independent review of the abstracts and titles of these publications identified 56 potentially relevant studies. Of these potentially relevant articles, eight studies met the inclusion criteria, with a total of 3118 patients being included in this systematic review. One potentially relevant abstract is awaiting assessment as detailed methodology and outcomes have not been possible to obtain (<a href="./references#CD003462-bbs2-0063" title="ZwernerP , GoreJ , CorraoJ , et al. Heparin in the treatment of unstable angina: a randomized prospective trial. Circulation1987;76(Suppl IV):IV-180. ">Zwerner 1987</a>). </p> <p>The 2014 update of the search resulted in 2681 extra citations. One review author (CAC) examined the titles and abstracts and retrieved full‐text articles where necessary. This resulted in the addition of nine new references to nine studies (<a href="./references#CD003462-bbs2-0014" title="BrownKW , MacMillanRL . Initial heparin therapy in acute myocardial infarction. Canadian Medical Association Journal1964;13(90):1345-8. ">Brown 1964</a>; <a href="./references#CD003462-bbs2-0017" title="CohenM , GensiniGF , MaritzF , GurfinkelEP , HuberK , TimermanA , et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. Journal of the American College of Cardiology2003;42(8):1348-56. ">Cohen 2003</a>; <a href="./references#CD003462-bbs2-0019" title="KedhiE , JoesoefKS , McFaddenE , WassingJ , vanMieghemC , GoedhartD , et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet2010;375(9710):201-9. ">COMPARE 2010</a>; <a href="./references#CD003462-bbs2-0021" title="YusufS , MehtaSR , XieC , AhmedRJ , XavierD , PaisP , et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes inpatients with acute myocardial infarction presenting with ST-segment elevation. JAMA2005;293(4):427-35. ">CREATE 2005</a>; <a href="./references#CD003462-bbs2-0036" title="MasselD , CruickshankMK . Enoxaparin in acute coronary syndromes: Evidence for superiority over placebo or untreated control. American Heart Journal2002;143(5):748-52. ">Massel 2002</a>; <a href="./references#CD003462-bbs2-0042" title="YusufS , MehtaSR , ChrolaviciusS , AfzalR , PogueJ , GrangerCB , et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA2006;295(13):1519-30. ">OASIS‐6 2006</a>; <a href="./references#CD003462-bbs2-0044" title="OldgrenJ , WallentinL , AfzalR , BassandJP , BudajA , ChrolaviciusS , et al. Effects of fondaparinux in patients withST-segment elevation acute myocardial infarction not receiving reperfusion treatment. European Heart Journal2008;29(3):315-23. ">Oldgren 2008</a>; <a href="./references#CD003462-bbs2-0046" title="PetersonJG , TopolEJ , RoeMT , SappSK , LincoffAM , DeckersJW , et al. Prognostic Importance of ConcomitantHeparin With Eptifibatide in AcuteCoronary Syndromes. American Journal of Cardiology2001;87(5):532-6. ">Peterson 2001</a>; <a href="./references#CD003462-bbs2-0055" title="TanajuraLFL , SousaAGMR , PintoIMF , ChavesAJ , CentemeroMP , FeresF , et al. Use of heparin in coronary angioplasty: randomized trial in low risk patients for abrupt closure [Heparina na Angioplastia Coronária. Estudo Randomizado emCasos com Baixo Risco Para Oclusão Aguda]. Arquivos Brasileiros de Cardiologia1993;60(2):95-8. ">Tanajura 1993</a>). Three additional myocardial infarction studies were considered for inclusion but all study participants had confirmed ST‐segment elevation myocardial infarction (STEMI) (<a href="./references#CD003462-bbs2-0014" title="BrownKW , MacMillanRL . Initial heparin therapy in acute myocardial infarction. Canadian Medical Association Journal1964;13(90):1345-8. ">Brown 1964</a>; <a href="./references#CD003462-bbs2-0021" title="YusufS , MehtaSR , XieC , AhmedRJ , XavierD , PaisP , et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes inpatients with acute myocardial infarction presenting with ST-segment elevation. JAMA2005;293(4):427-35. ">CREATE 2005</a>; <a href="./references#CD003462-bbs2-0042" title="YusufS , MehtaSR , ChrolaviciusS , AfzalR , PogueJ , GrangerCB , et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA2006;295(13):1519-30. ">OASIS‐6 2006</a>).These studies therefore needed to be excluded. The main reasons for exclusion of the rest of the studies that appeared eligible for this review were (a) not a randomized controlled trial, and (b) heparin not compared versus placebo. The full list of excluded studies and reasons for exclusion are given in the <a href="./references#CD003462-sec-0074" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD003462-sec-0036"> <h4 class="title">Included studies</h4> <p>There were no new included studies for this update. Eight studies with a total of 3118 patients treated with either UFH or LMWH were included. In total, 1602 patients (52%) were eligible to receive LMWH and 1508 patients (48%) were eligible to receive UFH. The average age at randomization was 62 years. The majority of trials enrolled male patients (75%) with unstable angina (<a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). </p> <p>Two different LMWHs were used: dalteparin (1498 eligible patients) and nadroparin (104 eligible patients). Of the patients receiving UFH, 19% were switched to warfarin when the UFH was discontinued. Most trials mandated that participants received study medication within 24 hours of the most recent episode of chest pain; however, some patients received it as late as 48 hours in two studies (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>) and up to 72 hours in two other studies (<a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>). The duration of treatment varied among the different studies with a range of two to seven days. Aspirin (75 to 325 mg per day) was a standard concomitant intervention in all of the studies. Treatment with other anti‐anginal medications (e.g. nitroglycerin, beta‐blockers and calcium channel blockers) was at the discretion of the attending physician in most studies. Patients were selected on the basis of narrow inclusion criteria. They had to have a history of unstable angina plus one of the following: a previous history of known coronary artery disease (defined as a prior myocardial infarction, positive exercise stress test or angiographic evidence), ECG changes, or cardiac enzyme elevation. One study (<a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>) stipulated that patients had to present with angina within two weeks to six months following coronary angioplasty. </p> <p>All studies were RCTs; however, not all were double blind. Three studies (<a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>) reported on outcomes only over the duration of the hospital admission. In one study (<a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>), only data from the in‐patient arm of the study was used although patients were followed up for five to seven months. In all other studies, however, the patients were followed up and the outcomes measured at three months. A variety of outcome measures were reported. Death, myocardial infarction, recurrent angina, revascularization and major bleeds were the most commonly reported outcomes across the studies. One study (<a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>) reported a combined end point of death or myocardial infarction and it was not possible to separate the individual event rates. Death was reported as 'all‐cause' and secondary to myocardial infarction in most studies. Myocardial infarction was clearly defined as typical chest pain associated with the appearance of new significant ECG changes (new ST‐T changes, loss of R‐wave amplitude or development of Q‐waves), and the subsequent elevation of serum cardiac enzymes (creatine kinase, plus or minus MB fraction) beyond levels drawn at enrollment. The definition of recurrent angina varied among the studies. Of the six papers which included recurrent angina as a study end point, three required a history of typical chest pain accompanied by ECG changes (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). The other three studies either did not require associated ST segment changes to diagnose recurrent angina or were unclear how they defined this end point (<a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>). The indications for revascularization were not well defined in most studies with 'severe refractory/recurrent ischemia' being the most common criteria. The definition of major bleeding complications was consistent across all studies. Minor bleeds and the incidence of thrombocytopenia were only reported in three and two studies respectively. </p> <p>The timing of the end points was inconsistent among the trials ranging from 48 hours to three months. In four studies, endpoints were recorded over a five‐ to eight‐day period (<a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>), while in the other four studies, end points were measured at three months (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). We have grouped the results for all reported time periods. </p> </section> </section> <section id="CD003462-sec-0037"> <h3 class="title">Risk of bias in included studies</h3> <p>For this update, two authors (CAC and NDF) independently assessed risk of bias of the trials. For this purpose, instructions given in <i>the Cochrane Handbook for Systematic Reviews</i> of Interventions (<a href="./references#CD003462-bbs2-0075" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Chichester (UK): John Wiley &amp; Sons, 2011.">Higgins 2011</a>) were followed. </p> <section id="CD003462-sec-0038"> <h4 class="title">Allocation</h4> <p>The sequence generation for participant allocation was adequate in only two studies (<a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). Both studies used blocked randomization to determine the allocation for the two comparison groups. In six studies, the method of sequence generation was unclear or not specified (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>). In relation to concealment of the allocation sequence, in two of the studies the pharmacy assigned eligible participants randomly (<a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>;). The rest of the studies provided insufficient information about concealment of the allocation sequence (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>). </p> </section> <section id="CD003462-sec-0039"> <h4 class="title">Blinding</h4> <p>Three trials adequately reported blinding of participants (<a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>), while only one study adequately reported blinding of assessors and personnel (<a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). Two trials did not blind participants, personnel, or outcome assessors (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>).Two trials did not blind participants and was unclear about the blinding of assessors (<a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>). Blinding of outcome assessors was unclear in five trials (<a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>). </p> </section> <section id="CD003462-sec-0040"> <h4 class="title">Incomplete outcome data</h4> <p>The number of missing data was equally distributed between treatment and control group in six trials (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). Two studies reported to have complete data for all included participants (<a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>). </p> </section> <section id="CD003462-sec-0041"> <h4 class="title">Selective reporting</h4> <p>No study protocol was available for the evaluated studies (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>), but all clinically expected outcomes were reported. Publication bias for the incidence of multiple end points (death or myocardial infarction) over all time periods was examined visually in the form of funnel plot. The funnel plot indicates that there may be publication bias (<a href="#CD003462-fig-0003">Figure 3</a>). However, the number of studies is considered insufficient to meet rigorous criteria for creating a funnel plot (<a href="./references#CD003462-bbs2-0081" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ2011;342:d4002.">Sterne 2011</a>). </p> <div class="figure" id="CD003462-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Incidence of multiple end points (death or myocardial infarction) over all time periods, outcome: 5.1 Heparin vs placebo or untreated control." data-id="CD003462-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Incidence of multiple end points (death or myocardial infarction) over all time periods, outcome: 5.1 Heparin vs placebo or untreated control. </p> </div> </div> </div> </section> <section id="CD003462-sec-0042"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies (<a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>) were stopped early. One of these trials was stopped early due to benefit with nadroparin and more bleeding with heparin (<a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>).The other study was discontinued prematurely on the basis of the policy board (<a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). </p> </section> </section> <section id="CD003462-sec-0043"> <h3 class="title" id="CD003462-sec-0043">Effects of interventions</h3> <p>See: <a href="./full#CD003462-tbl-0001"><b>Summary of findings 1</b> Heparin versus placebo for non‐ST elevation acute coronary syndromes</a> </p> <p>As the timing of outcomes varied between studies, the results are tabulated over all time periods. </p> <section id="CD003462-sec-0044"> <h4 class="title">Primary outcomes</h4> <p><b>Death</b> </p> <p>Death was reported as an outcome in six trials involving 2426 patients (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). The incidence of death in those treated with placebo was 0.9% (11/1188) compared to 0.7% (9/1238) in those treated with an heparin. Overall, there was a trend towards fewer deaths in the heparin group compared to the placebo group; however, this was not statistically significant (risk ratio (RR) = 0.84, 95% confidence interval (CI) 0.36 to 1.98, P = 0.82, I<sup>2</sup> = 0%) (<a href="./references#CD003462-fig-0004" title="">Analysis 1.1</a>). </p> <p><b>Myocardial infarction</b> </p> <p>Myocardial infarction was reported as an outcome in six trials involving 2426 patients (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). Heparins were superior to placebo in preventing myocardial infarction (RR = 0.40, 95% CI 0.25 to 0.63, P = 0.63, I<sup>2</sup> = 0.0%). The overall incidence of myocardial infarction was 4.8% (57/1188) in those treated with placebo compared to 1.9% (24/1238) in those treated with heparin. Given the risk difference of ‐0.03 (95% CI ‐0.01 to ‐0.04), 33 (95% CI 25 to 100) patients would need to be treated with either type of heparin to prevent one additional myocardial infarction in patients presenting with acute coronary syndromes (<a href="./references#CD003462-fig-0005" title="">Analysis 2.1</a>). </p> <p><b>Major bleeds</b> </p> <p>All eight trials, involving 3118 patients, reported major bleeds as an outcome (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). Major bleeding was defined as a fall in hemoglobin of more than 2 g/dL, or bleeding leading to transfusion in seven trials (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). The RISC trial reported no major bleeds (<a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>). There was a trend towards more major bleeds in the heparin studies compared to control studies (RR = 2.05, 95% CI 0.91 to 4.60, I<sup>2</sup> = 0.0%). In the two studies that treated patients with warfarin after initial heparin (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>), there was a trend towards more major bleeds (RR = 7.26, 95% CI 0.38 to 138). No heterogeneity was observed in this outcome (P = 0.93) (<a href="./references#CD003462-fig-0009" title="">Analysis 6.1</a>). </p> </section> <section id="CD003462-sec-0045"> <h4 class="title">Secondary outcomes</h4> <p><b>Recurrent angina</b> </p> <p>Recurrent angina was reported as an outcome in six studies involving 2426 patients (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). There was evidence of heterogeneity in this data set (P &lt; 0.01) and a random‐effects model was used to calculate the pooled statistic. Although heparins as a group showed a trend towards preventing recurrent angina compared to placebo, this result was not statistically significant (RR = 0.81, 95% CI 0.60 to 1.09; I<sup>2</sup> = 65.0%) (<a href="./references#CD003462-fig-0006" title="">Analysis 3.1</a>). </p> <p><b>Revascularization procedures</b> </p> <p>The need for a revascularization procedure was reported as an outcome in six of the eight included studies involving 2520 patients (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). The pooled results from these studies failed to demonstrate a benefit of heparins compared to aspirin plus placebo in preventing revascularization procedures (RR = 0.93, 95% CI 0.76 to 1.15, I<sup>2</sup> = 41.1%) (<a href="./references#CD003462-fig-0007" title="">Analysis 4.1</a>). </p> <p><b>Multiple end points</b> </p> <p>We were able to calculate the incidence of death or myocardial infarction for all eight included studies (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). Patients who were treated with heparins were less likely to experience one of these outcomes compared to those treated with placebo (RR = 0.61, 95% CI 0.47 to 0.80, I<sup>2</sup> = 26.5%). No significant heterogeneity was identified in this result (P = 0.22). The incidence of death or myocardial infarction was 4.9% (79/1602) for patients treated with heparins compared to 7.6% (115/1508) for those treated with placebo. Given a risk difference of ‐0.03 (95% CI ‐0.01 to ‐0.05), 33 (95% CI 20 to 100) patients would need to be treated with heparin to prevent one additional death or myocardial infarction (<a href="./references#CD003462-fig-0008" title="">Analysis 5.1</a>). </p> <p><b>Minor bleeds</b> </p> <p>Only three of the eight included studies (n = 1931) reported minor bleeds as an outcome (<a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>). Data from the analysis indicated heterogeneity (P &lt; 0.03) so a random‐effects model was used to pool data. Patients who were treated with heparins experienced significantly more minor bleeds compared to patients treated with placebo (RR = 6.80, 95% CI 1.23 to 37.49, I<sup>2</sup> = 66.9%). In the heparin group, 8.0% (79/989) of patients experienced minor bleeding compared to only 0.5% (5/942) in control group. This represents a risk difference of 0.06 (95% CI 0.02 to 0.11), such that for every 17 (95% CI 9 to 50) patients treated with heparin, one additional case of minor bleeding was observed (<a href="./references#CD003462-fig-0010" title="">Analysis 7.1</a>). </p> <p><b>Thrombocytopenia</b> </p> <p>Only two studies (n = 1717) reported the outcome of thrombocytopenia (<a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>). From this limited data set, there appeared to be no difference between patients treated with heparins compared to control in the occurrence of thrombocytopenia (RR = 0.20, 95% CI 0.01 to 4.24, I<sup>2</sup> = 0.0%) (<a href="./references#CD003462-fig-0011" title="">Analysis 8.1</a>). </p> </section> <section id="CD003462-sec-0046"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analysis based on random‐effects versus fixed‐effect modeling yielded very similar overall results. With the exception of recurrent angina, the pooled statistic for all other outcomes was essentially unchanged regardless of whether a random‐effects or fixed‐effect model was chosen. If a fixed‐effect instead of a random‐effects model had been used for recurrent angina, the point estimate would have essentially remained unchanged; however, the narrowed 95% CIs would result in a statistically significant reduction of recurrent angina with heparins compared to aspirin alone (RR = 0.79, 95% CI 0.67 to 0.93). The trial quality assessment eliminated four papers, approximately 25% of enrolled participants. When this sensitivity analysis (e.g. excluding these studies) was performed, there were no important changes in these pooled results. </p> </section> <section id="CD003462-sec-0047"> <h4 class="title">Subgroup analysis</h4> <p>Subgroup analysis based on whether patients had unstable angina versus a NSTEMI was not possible in this review, since subgroup data could not be obtained from the studies. </p> <p>Subgroup comparisons based on whether UFH or LMWH was used were difficult to make due to small study numbers. Of the eight included studies, only two (<a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>) compared LMWH versus placebo. It is interesting to note, however, that only the LMWH subgroup showed a statistically significant benefit over the control group in any of the outcomes studies. Higgins and Thompson (<a href="./references#CD003462-bbs2-0074" title="HigginsJP , ThompsonSG , DeekJJ , AltmanDG . Bias in meta-analysis detected by a simple, graphical test.. BMJ2003;327:557-60.">Higgins 2003</a>) propose the I<sup>2</sup> statistic which describes the percentage of total variation across studies due to heterogeneity rather than chance. Using their methods, significant and important heterogeneity was identified with respect to the incidence of recurrent angina (P = 0.01 and I<sup>2</sup> = 65%) and revascularization procedures (P = 0.12 and I<sup>2</sup> = 41%). When the data were analyzed according to the treatment received, clinically important subgroups were identified. The pooled analysis from the LMWH subgroup showed statistically significant benefit with respect to the incidence of recurrent angina (P = 0.52; 95% CI 0.36 to 0.74) and revascularization procedures (P = 0.26; 95% CI: 0.09 to 0.78), even though this benefit was lost when all heparins were grouped together. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003462-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003462-sec-0048"></div> <p>This systematic review examined the best available evidence for the use of heparins in the treatment of non‐ST elevation acute coronary syndromes and identified several important outcomes related to their use. Overall, heparins as a group failed to demonstrate a statistically significant reduction in mortality, although a beneficial effect as great as a 64% reduction or an increased risk of 98% can not be excluded. Given the low incidence of death in the included studies (~1% to 2%), this systematic review is under‐powered to detect small treatment differences. For this outcome, the systematic review had 80% power to detect a relative reduction in risk of 84% (from 0.93% to 0.15%). Approximately 4900 patients in each group would have been required to detect a 50% relative reduction in risk (power = 80%, two‐sided alpha = 0.05). Treatment with heparins did, however, reduce the incidence of myocardial infarction such that 33 patients needed to be treated with heparin to prevent one additional myocardial infarction. For most of the other outcomes, the benefit of using heparins was less clear. </p> <p>Half of all participants randomized to receive heparin in this review were eligible to receive LMWH. When these studies were pooled, LMWH proved to be superior to placebo, not only with reducing the incidence of myocardial infarction, but also with reducing the incidence of recurrent angina and the need for revascularization procedures. Again, although statistically significant, the absolute risk reductions were small (1% to 3%), suggesting caution in the clinical interpretation of these findings. </p> <p>Overall, little heterogeneity was identified in the pooled results reported in this review. This is not surprising given that non‐ST elevation acute coronary syndromes represent a well‐defined disease spectrum with fairly clear‐cut dichotomous outcomes. Outcomes in which heterogeneity was identified included the incidence of recurrent angina and minor bleeds (I<sup>2</sup> = 65% and 67%, respectively). A moderate degree of heterogeneity was identified (I<sup>2</sup> = 41%) in the incidence of revascularization procedures. This can in part be accounted for by subtle differences in study design: inclusion criteria, dosing regimen, UFH versus LMWH use and timing of outcomes. To a larger extent, however, this heterogeneity may reflect the particular outcomes in question, the definitions of which varied between studies and local practices relating to revascularization procedures. </p> <p>Overall, heparins appeared to be a safe treatment for non‐ST elevation acute coronary syndromes. Although there was a trend towards more major bleeds in the heparin‐treated group, this was not statistically significant. Not surprisingly, patients treated with heparins had a higher incidence of minor bleeding. It is difficult to comment on the rate of thrombocytopenia as only two studies commented on this rare, but potentially life‐threatening complication of heparinization. This data must be interpreted with caution, however, as side‐effects were poorly reported in most studies. </p> <p>There is a possibility of publication bias in this systematic review. For example, by missing unpublished 'statistically' negative trials we may be over‐estimating the effect of heparin treatment. However, a comprehensive search of the published literature for potentially relevant studies was conducted, using a systematic strategy to avoid bias. This was followed by attempts to contact corresponding and first authors. Although no unpublished or negative trials were identified, we recognize that these types of trials may exist. The funnel plot demonstrates asymmetry in the area of small negative trials, so this is a legitimate concern. Given the nature of the research (e.g. expensive, complex, difficult to fund), however, these small negative trials are unlikely, and would not be expected to influence the results. There is also a possibility of study selection bias. Four trials in which the study group did not receive aspirin or were compared versus a non‐aspirin control were excluded (<a href="./references#CD003462-bbs2-0009" title="AverkovOV , ZateischikovDA , GratsianskyNA , LogutovYA , YavelovIS , YanusVM . Unstable angina pectoris: aspirin and heparin in a double-blind placebo-controlled study, their effects on the outcojjme of disease during hospitalization. Kardiologiya1993;33(5):4-9. ">Averkov 1993</a>; <a href="./references#CD003462-bbs2-0015" title="CharvatJ , KuruvillaT . Comparative study of heparin and antiplatelets in treatment of preinfarction angina. Cardiologia1989;34:146-54. ">Charvat 1989</a>; <a href="./references#CD003462-bbs2-0053" title="SerneriGGN , ModestiPA , GensiniGF , BranziA , MelandriG , PoggesiL , et al. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group. Lancet1995;345(8959):1201-4. ">Serneri 1995</a>; <a href="./references#CD003462-bbs2-0057" title="ThérouxP , WatersD , QiuS , McCansJ , deGuiseP , JuneauM . Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation1993;88(5 Pt 1):2045-8. ">Théroux 1993</a>) because of the well‐accepted treatment of acute coronary syndromes with aspirin (<a href="./references#CD003462-bbs2-0077" title="Lewis HD Jr, DavisJW , ArchibaldDG , SteinkeWE , SmithermanTC , Doherty JE 3rd, et al. Proctective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results for a Veterans Administration Cooperative Study. New England Journal of Medicine1983;309(7):396-403.">Lewis 1983</a>; <a href="./references#CD003462-bbs2-0045" title="OlerA , WhooleyMA , OlerJ , GradyD . Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA1996;276:811-5. ">Oler 1996</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). However, we used two independent review authors, and feel confident that the studies excluded were done so for consistent and appropriate reasons. Our search was comprehensive and has been updated, so it is unlikely that we missed any published trials. Most studies restricted enrollment to patients who had either a documented history of coronary artery disease, ECG changes or cardiac enzyme elevation, which is somewhat different from the patient population traditionally treated with heparins for acute coronary syndrome (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). </p> <p>In recent years, the administration of clopidogrel in addition to aspirin and heparin has been shown to be of benefit as initial medical treatment of patients with unstable angina and NSTEMI. Following the results of the CURE trial (<a href="./references#CD003462-bbs2-0085" title="YusufS , ZhaoF , MehtaSR , ChrolaviciusS , TognoniG , Fox KK Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine2001;345(7):494-502.">Yusuf 2001</a>), dual antiplatelet treatment with clopidogrel combined with aspirin became the standard of care in patients with NSTEACS (<a href="./references#CD003462-bbs2-0064" title="AndersonJL , AdamsCD , AntmanEM , BridgesCR , CaliffRM, Casey DE Jr, et al. 2012 ACCF/AHA focused update incorporated into the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines. Journal of the American College of Cardiology2013;61(23):e179–347.">ACCF/AHA Guideline NSTEACS 2013</a>; <a href="./references#CD003462-bbs2-0071" title="HammCW , BassandJP , AgewallS , BaxJ , BoersmaE , BuenoH , et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal2011;32(23):2999-3054.">ESC Guidelines NSTEACS 2011</a>). The evidence evaluated in this review comes from older trials where the use of P2Y12 receptor blockers were not in wide use. Thus, the results of our meta‐analysis may not be totally applicable to patients with NSTEACS treated with dual antiplatelet therapy. Recent systematic reviews and meta‐analyses of randomized controlled trials have shown that dual therapy with aspirin and clopidogrel is beneficial in patients with acute coronary syndromes with a favorable benefit‐risk profile (<a href="./references#CD003462-bbs2-0066" title="BowryAD , BrookhartMA , ChoudhryNK . Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. American Journal of Cardiology2008;101(7):960-6.">Bowry 2008</a>; <a href="./references#CD003462-bbs2-0072" title="EshaghianS , KaulS , AminS , ShahPK , DiamondGA . Role of clopidogrel in managing atherothrombotic cardiovascular disease. Annals of Internal Medicine2007;146(6):434-41.">Eshaghian 2007</a>; <a href="./references#CD003462-bbs2-0086" title="ZhouYH , WeiX , LuJ , YeXF , WuMJ , XuJF , et al. Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PloS One2012;7(2):e316242.">Zhou 2012</a>). However, as antiplatelet therapy becomes more potent, bleeding risk has become a concern (<a href="./references#CD003462-bbs2-0086" title="ZhouYH , WeiX , LuJ , YeXF , WuMJ , XuJF , et al. Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PloS One2012;7(2):e316242.">Zhou 2012</a>). </p> <p>This systematic review illustrates the potential benefit of using heparins in the early treatment of non‐ST elevation acute coronary syndromes. These results are concordant with the most current recommendations made by the American Heart Association (<a href="./references#CD003462-bbs2-0064" title="AndersonJL , AdamsCD , AntmanEM , BridgesCR , CaliffRM, Casey DE Jr, et al. 2012 ACCF/AHA focused update incorporated into the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines. Journal of the American College of Cardiology2013;61(23):e179–347.">ACCF/AHA Guideline NSTEACS 2013</a>) and similar to two previous reviews (<a href="./references#CD003462-bbs2-0070" title="EikelboomJW , AnandSS , MalmbergK , WeitzJI , GinsbergJS , YusufS . Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet2000;355(9219):1936-42.">Eikelboom 2000</a>; <a href="./references#CD003462-bbs2-0045" title="OlerA , WhooleyMA , OlerJ , GradyD . Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA1996;276:811-5. ">Oler 1996</a>).The AHA suggests using either LMWH or UFH in patients with unstable angina/NSTEMI in addition to antiplatelet therapy as soon as possible after presentation. </p> <section id="CD003462-sec-0049"> <h3 class="title" id="CD003462-sec-0049">Quality of evidence</h3> <p>A total of eight studies were included in this review with a total of 3118 patients. According to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the quality of the evidence was low for all clinically important outcomes. All the included studies were prospective, randomized controlled trials but only one of the included studies was assessed at low risk of bias (<a href="./references#CD003462-bbs2-0008" title="ThérouxP , OuimetH , McCansJ , LatourJG , JolyP , LévyG , et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine1988;319(17):1105-11. ">Théroux 1988</a>). For all domains, five studies (62%) were at unclear risk of bias for at least one domain (<a href="./references#CD003462-bbs2-0003" title="DoucetS , MalekianpourM , TherouxP , BilodeauL , CoteG , GuiseP , et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation2000;101(9):955-61. ">Doucet 2000</a>; <a href="./references#CD003462-bbs2-0004" title="SwahnE , WallentinL . Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology1997;80:25E-29E. WallentinL . Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996;347(9001):561-8. ">FRISC 1996</a>; <a href="./references#CD003462-bbs2-0006" title="HoldrightD , PatelD , CunninghamD , ThomasR , HubbardW , HendryG , et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology1994;24(1):39-45. ">Holdright 1994</a>; <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>; <a href="./references#CD003462-bbs2-0007" title="WallentinL . Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet1990;336(8719):830-7. ">RISC 1990</a>). Three of the included studies were at high risk of bias in two domains (<a href="./references#CD003462-bbs2-0001" title="CohenM , AdamsPC , HawkinsL , BachM , FusterV . Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology1990;66(19):1287-92. ">Cohen 1990</a>; <a href="./references#CD003462-bbs2-0002" title="CohenM , AdamsPC , ParryG , XiongJ , ChamberlainD , WieczorekI , et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation1994;89(1):81-9. ">Cohen 1994</a>, <a href="./references#CD003462-bbs2-0005" title="GurfinkelEP , ManosEJ , MejailRI , CerdaMA , DurontoEA , GarciaCN , et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology1995;26(2):313-8. ">Gurfinkel 1995</a>) see <a href="./full#CD003462-tbl-0001">summary of findings Table 1</a>. </p> <p>Regarding the quality of evidence, we conclude that there is insufficient evidence to draw meaningful conclusions about the benefits and harms of heparins in non‐ST elevation acute coronary syndromes. Overall, the methodological quality of trials was far from optimal. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003462-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-FIG-01" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003462-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003462-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Incidence of multiple end points (death or myocardial infarction) over all time periods, outcome: 5.1 Heparin vs placebo or untreated control." data-id="CD003462-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Incidence of multiple end points (death or myocardial infarction) over all time periods, outcome: 5.1 Heparin vs placebo or untreated control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Incidence of death over all time periods, Outcome 1: Heparin vs placebo or untreated control" data-id="CD003462-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Incidence of death over all time periods, Outcome 1: Heparin vs placebo or untreated control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Incidence of MI over all time periods, Outcome 1: Heparin vs placebo or untreated control" data-id="CD003462-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Incidence of MI over all time periods, Outcome 1: Heparin vs placebo or untreated control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Incidence of recurrent angina over all time periods, Outcome 1: Heparin vs placebo or untreated control" data-id="CD003462-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Incidence of recurrent angina over all time periods, Outcome 1: Heparin vs placebo or untreated control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Incidence of revascularization procedures over all time periods, Outcome 1: Heparin vs placebo or untreated control" data-id="CD003462-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Incidence of revascularization procedures over all time periods, Outcome 1: Heparin vs placebo or untreated control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Incidence of multiple end points (death or myocardial infarction) over all time periods, Outcome 1: Heparin vs placebo or untreated control" data-id="CD003462-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Incidence of multiple end points (death or myocardial infarction) over all time periods, Outcome 1: Heparin vs placebo or untreated control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Incidence of major bleeds over all time periods, Outcome 1: Heparin vs placebo or untreated control" data-id="CD003462-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Incidence of major bleeds over all time periods, Outcome 1: Heparin vs placebo or untreated control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Incidence of minor bleeds over all time periods, Outcome 1: Heparin vs placebo or untreated control" data-id="CD003462-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Incidence of minor bleeds over all time periods, Outcome 1: Heparin vs placebo or untreated control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003462-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/urn:x-wiley:14651858:media:CD003462:CD003462-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Incidence of thrombocytopenia over all time periods, Outcome 1: Heparin vs placebo or untreated control" data-id="CD003462-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_t/tCD003462-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Incidence of thrombocytopenia over all time periods, Outcome 1: Heparin vs placebo or untreated control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/media/CDSR/CD003462/image_n/nCD003462-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003462-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin versus placebo for non‐ST elevation acute coronary syndromes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Heparin versus placebo for non‐ST elevation acute coronary syndromes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with non‐ST elevation acute coronary syndromes<br/><b>Settings:</b> Inpatients<br/><b>Intervention:</b> Heparin<br/><b>Comparison:</b> Placebo or untreated control </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Heparin + ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 5‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.84</b> <br/>(0.36 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2426<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low due to study limitations and imprecision</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(3 to 18) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of myocardial infarction</b><br/>Follow‐up: 5‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.4</b> <br/>(0.25 to 0.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2426<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low quality because of very serious study limitations</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(12 to 30) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(15 to 37) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Recurrent angina</b><br/>Follow‐up: 5‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.81</b> <br/>(0.6 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2426<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Very low due to study limitations and inconsistency</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>166 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>134 per 1000</b><br/>(99 to 181) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>361 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b><br/>(217 to 393) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of revascularization procedures</b><br/>Follow‐up: 5‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b> <br/>(0.76 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2520<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low quality because of very serious study limitations</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b><br/>(73 to 111) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b><br/>(103 to 155) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Major hemorrhage</b><br/>Follow‐up: 2‐150 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.05</b> <br/>(0.91 to 4.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3118<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low quality because of very serious study limitations</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b><br/>(4 to 21) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Allocation concealment was uncertain in the majority of the evaluated trials. Lack of blinding of participants and outcome assessors in two trials, blinding of outcome assessors is uncertain in three trials. Final decision: rate down by one level (lack of blinding not considered a serious study limitation for the outcome of all‐cause mortality). Two trials stopped early for benefit; stopping early as a source of bias is questionable. Final decision was not to rate down for stopping early for benefit.<br/><sup>2</sup> Wide confidence intervals and few events. We decided to rate down for imprecision because confidence intervals fails to exclude important benefit or important harm.<br/><sup>3</sup> Funnel plot could be interpreted as suggesting of publication bias. However, the number of studies is insufficient to meet rigorous criteria for creating a funnel plot. Final decision: publication bias is speculative (not rate down).<br/><sup>4</sup> Allocation concealment was uncertain in the majority of the evaluated trials. Lack of blinding of participants in four trials, lack of blinding of outcome assessors in two trials, blinding of outcome assessors is uncertain in three trials. Final decision: rate down by two levels.Two trials stopped early for benefit; stopping early as a source of bias is questionable. Final decision was not to rate down for stopping early for benefit.<br/><sup>5</sup> Allocation concealment was uncertain in the majority of the evaluated trials. Lack of blinding of participants in four trials, lack of blinding of outcome assessors in two trials, blinding of outcome assessors is uncertain in five trials. Final decision: rate down by two levels.Two trials stopped early for benefit; stopping early as a source of bias is questionable. Final decision was not to rate down for stopping early for benefit. </p> <p><sup>6</sup> Results were inconsistent across studies as evidenced by I² = 65% </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin versus placebo for non‐ST elevation acute coronary syndromes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/full#CD003462-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003462-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Incidence of death over all time periods</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Heparin vs placebo or untreated control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.36, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.33, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 UFH + warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.15, 7.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Incidence of death over all time periods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003462-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Incidence of MI over all time periods</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Heparin vs placebo or untreated control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.25, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.14, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.23, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 UFH + warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.25, 1.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Incidence of MI over all time periods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003462-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Incidence of recurrent angina over all time periods</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Heparin vs placebo or untreated control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.36, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 UFH + warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.45, 1.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Incidence of recurrent angina over all time periods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003462-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Incidence of revascularization procedures over all time periods</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Heparin vs placebo or untreated control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.09, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 UFH + warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.75, 1.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Incidence of revascularization procedures over all time periods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003462-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Incidence of multiple end points (death or myocardial infarction) over all time periods</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Heparin vs placebo or untreated control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.47, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.18, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.58, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 UFH + warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.15, 1.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Incidence of multiple end points (death or myocardial infarction) over all time periods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003462-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Incidence of major bleeds over all time periods</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Heparin vs placebo or untreated control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.91, 4.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.43, 5.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.59, 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 UFH + warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.26 [0.38, 138.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Incidence of major bleeds over all time periods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003462-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Incidence of minor bleeds over all time periods</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Heparin vs placebo or untreated control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.80 [1.23, 37.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.96 [0.56, 177.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.24 [0.68, 186.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 UFH + warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [0.64, 9.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Incidence of minor bleeds over all time periods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003462-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Incidence of thrombocytopenia over all time periods</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Heparin vs placebo or untreated control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 UFH + warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Incidence of thrombocytopenia over all time periods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003462.pub3/references#CD003462-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003462.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003462-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003462-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003462-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="fr#CD003462-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003462-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD003462-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003462-note-0008">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003462-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003462\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003462\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003462\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003462\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003462\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003462.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003462.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003462.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003462.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003462.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715351906"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003462.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715351910"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003462.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d84fef8e1f446',t:'MTc0MDcxNTM1Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 